Sarepta Therapeutics, Inc. (SRPT)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 2
Do Nothing: fundamentalScore is 2 (below the required floor of 3) and qualitativeScore is 2 (below the required floor of 3), so the strategy's override gates block any bullish entry regardless of the chart; the chart itself is weak-bearish (price below every moving average, MACD -0.53 expanding, RSI 37.3, rising ADX) and no alternative setup rescues it — a pullback limit would be countertrend (price < SMA50 with MACD < 0) with no plan built under the hard block, and no breakout stop qualifies either since the nearest settled resistance at 16.78-18.05 is 4.4%-12.3% above price, far more than one ATR of clearance.
Company overview
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on genetic treatments for rare diseases, specializing in RNA-targeted therapeutics and gene therapies. It offers treatments for Duchenne muscular dystrophy and has a pipeline including exon-skipping and gene therapy candidates.
Fundamental
weakSarepta's fundamentals are weak and inconsistent, with a contracting product franchise and high regulatory risks despite adequate liquidity.
Sarepta has a roughly $2 billion revenue base, about $1 billion of cash plus an undrawn revolver, and positive trailing free cash flow, but its product franchise is contracting sharply after the ELEVIDYS safety events, 2026 GAAP profit comes from a one-time $325 million Roche option payment rather than operations, and the PMO portfolio faces a February 2027 FDA decision after a failed confirmatory trial. High-risk, binary, weak and inconsistent fundamentals despite adequate near-term liquidity.
Sentiment
weakSentiment is bearish due to a Q3 earnings miss and unresolved FDA safety concerns.
Dominant driver is the Q3 2026 print (confidence: announced, 2026-11-05) — an adjusted EPS miss ($0.13 vs $0.37 consensus) with Elevidys revenue declining and the stock scored down, still being digested nine days later — layered on an unresolved FDA/ELEVIDYS safety overhang. The measured media delta is determinately negative (baseline polarity_score ≈ +0.10 on 4 unique on-topic items → scoring ≈ −0.10 on 12 items, a ≈ −0.20 move out of mildly positive territory), and a moderate red-flag cap applies for confirmed material securities litigation plus conflicting catalyst signals (a fresh Deutsche Bank upgrade against maintained Sell ratings and a Hold consensus) — with no market-rewarded bullish catalyst in the scored coverage, the array is bearish-tilted rather than genuinely mixed.
Technical
weakThe stock is in a downtrend, trading below all key moving averages with negative momentum indicators.
SRPT's chart is weak-to-bearish. Price 16.07 sits below the SMA20 (17.95), SMA50 (18.59), SMA200 (18.52), EMA9 (17.00), EMA21 (17.61), WMA9 (16.77) and WMA21 (17.61) — a fully inverted moving-average stack — and is only above the TEMA14 (16.27) and the 16.01 daily VWAP. MACD is negative and expanding (-0.53 line vs -0.29 signal, histogram -0.25 versus -0.18 two sessions ago), RSI14 at 37.34 has not reset into oversold, and ADX14 has climbed from 12.14 to 15.59 while the stock prints lower highs and lower lows, which reads as a developing downtrend rather than a bottom. Williams %R at -90.70 is the only deeply overbought/oversold extreme and points at best to a reflex bounce inside that downtrend. ATR14 of 0.94 is 5.85% of price, so each normal session spans a wide band relative to a 16-handle stock. Dollar volume is healthy (~$33.6M/day on a 20-day average) and the tape is distributing: the 2026-11-10 -6.65% repricing traded 3.36M shares against 1.32M on the mild 2026-11-13 bounce. Chart quality scores 2 (bounce-only). The fundamental override (fundamentalScore 2) and the qualitative override (qualitativeScore 2) both block any long entry regardless of the chart.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

